

The Premier Event for Building Drug Discovery Innovations & Collaborations

MONDAY
September 28

SYMPOSIA

- Induced Proximity-Based Drug Discovery
- Generative AI/Machine Learning-Driven Drug Design

TRAINING SEMINARS

- AI-Driven Design of Biologics: State-of-the-Art ML Models & Real-World Applications
- The End Game: From Lead Optimization to Drug Candidate Selection
- Drug Exposure at the Target: The Role of ADME and Pharmacokinetics

SHORT COURSES

- **MORNING 9:00-11:00**
SC1A: Protein Degradation from a Beyond-Rule-of-Five and an ADME Perspective
SC2A: Biophysical Approaches for GPCRs
SC3A: Next-Gen ADCs, Advanced Linkers & Conjugates: Mastering Design, Linker Optimization & Stability
- **AFTERNOON 1:30-3:30**
SC4A: DNA-Encoded Libraries in Drug Discovery: Design, Screening, and Lead Development
SC5A: Advanced Molecular Pharmacology for Drug Discovery: Traps, Tips, and Tricks
SC6A: Chemical Biology for Covalent Drug Discovery, Phenotypic Screening, and Target Deconvolution
- **EVENING 4:00-6:00**
SC7A: Building Agentic AI Workflows for Drug Discovery: From LLM Tools to Autonomous Discovery Pipelines
SC8A: Best Practices for Targeting GPCRs, Ion Channels, and Transporters
SC9A: Fragment-Based Drug Design: Advancing Tools and Technologies

SMALL MOLECULES & PEPTIDES

EMERGING DRUG TARGETS

- Cancer Targets: Degradation & Chemical Small Molecule Approaches
- Autoimmunity & CNS: PPI Modulators
- Obesity: Bound Peptides & Beyond

NOVEL DRUG MODALITIES

- PROTACs/Degraders, Molecular Glues and Proximity Inducers
- Peptides & Small Molecule Conjugates
- AI/ML and Screening Tools for Discovering New Drug Entities

TUESDAY September 29 — **THURSDAY** October 1

LEAD GENERATION STRATEGIES

- Biophysical Approaches
- GPCR-Targeted Discovery
- Library Innovations: DEL, FBDD, Covalent, D2B

INNOVATIVE DISCOVERY TECHNOLOGIES

- AI/ML-Enabled Target Identification and Lead Discovery
- Functional Proteomics for Direct-to-Biology Applications
- Phenotypic and Complex *In Vitro* Models and Assays

BIOLOGICS & RADIOLIGANDS

TUESDAY September 29 — **THURSDAY** October 1

ANTIBODIES AGAINST CHALLENGING TARGETS

- AI, Structural Validation and Novel Screening
- Intelligent Modalities and Precision Engineering
- Targeting Membrane Proteins and Restrictive Barriers

NEXT-GENERATION CONJUGATES

- Next-Generation Targeting and Delivery
- Linker Chemistry and Conjugation Methods
- Emerging Modalities and Computational Approaches for Conjugates

RADIOLIGAND THERAPIES

- Engineering Optimized Ligands, Linkers, and Radionuclides
- New Targets, Mechanisms, and Combinations
- Personalized Dosimetry and Theranostics